NTRA stock news · Natera, Inc.
Get alerts for NTRA
Follow Natera, Inc. (NTRA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NTRANatera's CEO, Steven Leonard Chapman, sold $2.38 million in shares, according to a recent SEC filing.
NeutralNatera's CEO sold 5,694 shares worth about $2.38 million and still owns 91,232 shares. The filing says nothing about company performance, so it does not change the business outlook.
Roth MKM starts following Natera and says to buy its stock.
Good for NTRARoth MKM began covering Natera with a Buy rating and a $475 share target. This new outside opinion points to a more positive view of the company.
Roth MKM starts following Natera and says to buy its stock.
Good for NTRARoth MKM began coverage of Natera with a Buy rating and a $475 target. This is a positive analyst view, though it reports no new company results.
Natera shares its earnings for the second quarter of 2026, including the full call transcript.
Good for NTRANatera's record test volume, sales growth, and new Signatera approvals point to a stronger business outlook, despite ongoing operating losses and a gross margin below its long-run goal.
On Friday, significant stock price increases were observed for Natera, Doximity, PubMatic, Airbnb, and several other major companies.
Good for NTRANatera and Doximity both reported strong quarterly results that exceeded analyst expectations and raised their future sales guidance, leading to significant stock price increases. This positive performance reflects strong demand and operational efficiency, which could attract further investor interest.
Natera's CEO indicates the firm is experiencing significant momentum following unprecedented test volumes and an upgraded forecast.
NeutralNatera's stock surged following a strong earnings report that exceeded Wall Street estimates, driven by record test volumes and a raised revenue outlook. The company's performance in oncology and women's health segments highlights its growth potential, making it a compelling investment opportunity.
Thursday's after-hours trading sees notable shifts in 12 health care stocks.
Good for NTRANatera's stock increased by 17.84% after its Q2 earnings report.